Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mevisiran
- Development stage
- Preclinical
- Lead developer
- EnhancedBio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Mevisiran, also known by its code name ENB401, is an siRNA drug developed by EnhancedBio, Inc. It functions as an inhibitor of phosphomevalonate kinase (PMVK), a cytosolic enzyme integral to the mevalonate pathway and isopentenyl diphosphate biosynthesis. The drug is delivered via lipid nanoparticles (LNP). By targeting and inhibiting PMVK, Mevisiran aims to act as a radio-sensitizer, particularly in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Overexpression of PMVK has been linked to poor prognosis in certain cancers, and its inhibition is expected to enhance the efficacy of chemo- and radio-therapeutic agents, thereby improving patient survival.
02
Targets
PMVK (Phosphomevalonate kinase)
Beyond the preview
Go deeper on Mevisiran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mevisiran.